FIELD: immunology.
SUBSTANCE: present invention refers to immunology. Antibody and its antigen-binding fragment capable of specific binding to PD-L1 are proposed. Also contemplated are a pharmaceutical composition, a nucleic acid, an encoding antibody or antigen-binding fragment thereof, an expression vector, a host cell, and a method for its production. In addition, a method for producing an antibody or antigen-binding fragment thereof, a method for inhibiting the biological activity of PD-L1, as well as the use of an antibody or antigen-binding fragment thereof or a pharmaceutical composition.
EFFECT: present invention may find further application in therapy of PD-L1 mediated disease or disorder, in particular various cancers.
29 cl, 19 dwg, 3 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO GD2 (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2796937C2 |
| MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS GITR | 2019 |
|
RU2734432C1 |
| MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
| ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO CD47 AND PD-L1 | 2021 |
|
RU2815823C2 |
| ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
| MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TO CD20 | 2018 |
|
RU2724469C2 |
| ANTIBODIES THAT BIND TO PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) | 2013 |
|
RU2689953C2 |
| BISPECIFIC ANTIBODIES SPECIFIC TO PD1 AND TIM3 | 2016 |
|
RU2729371C1 |
| ANTIBODIES TO CANINE PD-1 | 2014 |
|
RU2761663C2 |
| ANTIBODIES AGAINST THE PROGRAMMED DEATH LIGAND (PD-L1) AND APPLICATION THEREOF | 2019 |
|
RU2761638C1 |
